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133Variation in smoking cessation after vascular
operations
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Objective: Smoking is the most important modiﬁable risk factor for patients with vascular disease. The purpose of this
study was to examine smoking cessation rates after vascular procedures and delineate factors predictive of postoperative
smoking cessation.
Methods: The Vascular Study Group of New England registry was used to analyze smoking status preoperatively and at
1 year after carotid endarterectomy, carotid artery stenting, lower extremity bypass, and open and endovascular
abdominal aortic aneurysm repair between 2003 and 2009. Of 10,734 surviving patients after one of these procedures,
1755 (16%) were lost to follow-up and 1172 (11%) lacked documentation of their smoking status at follow-up. The
remaining 7807 patients (73%) were available for analysis. Patient factors independently associated with smoking
cessation were determined using multivariate analysis. The relative contribution of patient and procedure factors
including treatment center were measured by c-pie analysis. Variation between treatment centers was further evaluated by
calculating expected rates of cessation and by analysis of means. Vascular Study Group of New England surgeons were
surveyed regarding their smoking cessation techniques (85% response rate).
Results: At the time of their procedure, 2606 of 7807 patients (33%) were self-reported current smokers. Of these,
1177 (45%) quit within the ﬁrst year of surgery, with signiﬁcant variation by procedure type (open abdominal aortic
aneurysm repair, 50%; endovascular repair, 49%; lower extremity bypass, 46%; carotid endarterectomy, 43%; carotid artery
stenting, 27%). In addition to higher smoking cessation rates with more invasive procedures, age >70 years (odds ratio
[OR], 1.90; 95% conﬁdence interval [CI], 1.30-2.76;P < .001) and dialysis dependence (OR, 2.38; 95%CI, 1.04-5.43; P[
.04) were independently associated with smoking cessation, whereas hypertension (OR, 1.23; 95% CI, 1.00-1.51; P [
.051) demonstrated a trend toward signiﬁcance. Treatment center was the greatest contributor to smoking cessation, and
there was broad variation in smoking cessation rates, from 28% to 62%, between treatment centers. Cessation rates were
higher than expected in three centers and signiﬁcantly lower than expected in two centers. Among survey respondents, 78%
offered pharmacologic therapy or referral to a smoking cessation specialist, or both. The smoking cessation rate for patients
of these surgeons was 48% compared with 33% in those who did not offer medications or referral (P < .001).
Conclusions: Patients frequently quit smoking after vascular surgery, and multiple patient-related and procedure-related
factors contribute to cessation. However, we note signiﬁcant inﬂuence of treatment center on cessation as well as broad
variation in cessation rates between treatment centers. This variation indicates an opportunity for vascular surgeons to
impact smoking cessation at the time of surgery. (J Vasc Surg 2013;57:1338-44.)Cigarette smoking is strongly associated with the devel-
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8In addition, smoking is associated with progression of
vascular disease, including the expansion4 and rupture of
AAA,5 an increased risk of ischemic stroke,6 and graft throm-
bosis after lower extremity bypass (LEB).7,8 Beyond the
long-term beneﬁts in primary and secondary prevention of
vascular disease, a systematic review of randomized con-
trolled trials for perioperative smoking cessation interven-
tions demonstrated decreased complication rates after
surgery.9 Similar ﬁndings were noted in a meta-analysis that
demonstrated a 40% relative risk reduction in total complica-
tions with preoperative smoking cessation.10
In the United States, the prevalence of cigarette
smoking has decreased from 42% in 1965 to 19% in
2010.11 As a result, former smokers have exceeded current
smokers since 2002.12 From a population health standpoint,
smoking cessation counseling has been demonstrated to be
cost-effective,13,14 potentially even more cost-effective than
treatment of hypertension and hypercholesterolemia.15
With this in mind, The Joint Commission has devel-
oped a Tobacco Cessation Performance Measure as a part
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point that hospitalization for medical or surgical illness can
represent an opportunity to encourage smoking cessation
and that use of smoking cessation interventions will poten-
tially be tracked in the future as a measure of quality.
The aim of this study was to assess smoking cessation in
patients after vascular operations. This included evaluating
rates of cessation after surgery and understanding them in
the context of patient factors and procedure type as well
as evaluating variation in smoking cessation rates by treat-
ment center across New England.
METHODS
Data were obtained from the Vascular Study Group of
New England (VSGNE), a regional cooperative developed
in 2002 to improve vascular surgery outcomes. Details of
this database have been published previously.17 The use
of deidentiﬁed research data from the VSGNE was
approved by the Committee for the Protection of Human
Subjects of Dartmouth Medical School. Patients under-
going carotid endarterectomy (CEA), carotid artery stent-
ing (CAS), infrainguinal LEB, endovascular AAA repair
(EVAR) and open AAA repair (oAAA) from 2003 to
2009 at 14 treatment centers participating in VSGNE
were analyzed.
Treatment center was deﬁned as a single-surgeon
group or hospital. For patients in the database undergoing
multiple procedures, only the ﬁrst procedure was analyzed.
Smoking status was patient-reported and recorded preop-
eratively and at the 1-year follow-up. Current smokers
(preoperatively deﬁned as having smoked within the past
year) were compared with never and prior smokers.
Smoking cessation rate at follow-up was calculated, and
factors associated with smoking cessation were determined.
A total of 11,519 patients underwent one of the above
procedures in the evaluated timeframe. Of these, 217
patients (1.9%) died before hospital discharge and 568
(4.9%) died before their 1-year follow-up assessment.
Among the surviving 10,734 patients (93% of all patients),
1755 (16%) were lost to follow-up and 1172 (11%) had 1-
year follow-up but did not have documentation of their
smoking status at that time. The remaining 7807 patients
(73% of the total available for follow-up) had 1-year
follow-up with smoking status recorded and comprised
the study cohort.
Univariate analysis was performed on this cohort using
c2 analysis for categorical variables and the t test for contin-
uous variables. A subsequent multivariable model was con-
structed from all preoperative, patient-level variables,
including procedure type, using backward stepwise logistic
regression. The relative contribution of patient characteris-
tics, procedure type, and treatment center were further
evaluated in a multivariable model using the Knaus/Wag-
ner c-pie method.18 In this analysis, one signiﬁcant variable
is sequentially removed and the model recalculated. The
percentage of c2 uniquely associated with each variable is
then calculated. From this one can infer the relative contri-
bution of each variable in the model.For a detailed examination of variation in cessation rates
between treatment center, our multivariable model of inde-
pendent predictors of smoking cessation was used to calcu-
late expected cessation rates at each institution with >30
data points (n ¼ 10). This was compared with the observed
rate by c2 test. Recognizing that patient-related and
procedure-related factors alone would incompletely predict
smoking cessation, we concurrently compared smoking
cessation rates across centers using analysis of means. This
method provides an expected range around the mean of
the entire cohort, corrects for sample size, and accounts
for factors not present in the multivariable model.
The perspective of VSGNE surgeons about smoking
cessation was evaluated with an informal eight-question
survey. Questions focused on physicians’ impressions of
smoking prevalence and rates of cessation in their patients
as well as the methods that they use to promote smoking
cessation (Supplementary Fig, online only). Of 54 surgeons
sent a survey, 46 (85%) responded. Survey responses were
compared with blinded surgeon-speciﬁc smoking cessation
rates by c2 analysis. The threshold of statistical signiﬁcance
for all analyses was P < .05.
RESULTS
Among the 7807 patients with known smoking status
at the time of follow-up, the vascular operations performed
were distributed as 12.8% oAAA repair (n ¼ 999), 11.3%
EVAR (n ¼ 881), 21.6% LEB (n ¼ 1684), 52.1% CEA
(n ¼ 4066), and 2.3% CAS (n ¼ 177). Of these patients,
2606 (33%) were current smokers, 3881 (50%) were
former smokers, and 1320 (17%) were never smokers. By
type of procedure, the rates of current smoking were 41%
for oAAA, 30% for EVAR, 41% for LEB, 29% for CEA,
and 32% for CAS. The univariate analysis of patient charac-
teristics is listed in Table I for smokers, never smokers, and
former smokers. Current smokers tended to be younger
than never or prior smokers. Although they were more
likely to have undergone a previous percutaneous periph-
eral intervention, they were less likely to have undergone
a coronary procedure. Current smokers were more likely
to have chronic obstructive pulmonary disease (COPD)
but less likely to have diabetes or hypertension. Further,
current smokers were more likely to undergo a LEB or
oAAA, were more likely to have longer hospital length of
stay (LOS), and were more likely to require postoperative
admission to the intensive care unit.
Patients lost to follow-up. Comparison of the 2927
patients without follow-up smoking status with the 7807
patients with follow-up smoking status demonstrated no
difference between these two groups in prevalence of
smoking, sex, and age, or in rates of diabetes, hypertension,
or COPD. Patients without follow-up were slightly more
likely to have dialysis-dependent renal failure (1% vs 2%;
P ¼ .002) or to have undergone a previous vascular
procedure (18% vs 16%; P ¼ .004).
Patient and procedure factors associated with
smoking cessation. The 2606 currently smoking patients
were followed up at a mean interval of 12 6 5.9 (standard
Table I. Univariate analysis of smokers, never smokers,
and prior smokers at the time of surgery
Variable
Smoking status
P
Current, % Never, % Prior, %
(n ¼ 2060) (n ¼ 1320) (n ¼ 3881)
Total 33 17 50
Male 65 54 71 <.001
Age, yearsa <.001
<50 6 1 1
50-59 22 7 8
60-69 39 21 28
$70 33 72 63
Previous cardiovascular procedure
LEB, CEA, AAA 17 12 17 <.001
CABG/PCI 23 30 36 <.001
Comorbidity
Diabetes 26 35 33 <.001
Hypertension 81 86 87 <.001
Dialysis dependent 1 2 1 .004
COPD 40 9 24 <.001
Living at home
preadmission
99 98 99 .21
Procedure type <.001
AAA repair
Open 41 9 50
Endovascular 30 12 58
LEB 41 15 44
CEA 29 21 50
CAS 32 16 52
Perioperative
Urgent or
emergent
procedure
13 12 11 .044
Length of stay
>2 days
42 32 37 <.001
Intensive care
unit stay
45 32 37 <.001
Discharge destinationa <.001
Home 92 87 90
Rehabilitation unit 6 8 6
Nursing home 3 5 4
AAA, Abdominal aortic aneurysm; CABG, coronary artery bypass grafting;
CAS, carotid artery stenting; CEA, carotid endarterectomy; COPD, chronic
obstructive pulmonary disease; LEB, lower-extremity bypass; PCI, percu-
taneous coronary intervention.
aColumn percent. Values have been rounded and may not sum to 100%.
Table II. Univariate analysis of patients who quit
compared with patients who continued to smoke at
1 year after surgery
Variable
Smoking status
P
Quit, % Continued, %
(n ¼ 1429) (n ¼ 1177)
Total 45 55
Male 67 65 .33
Age, yearsa <.001
<50 5 7
50-59 20 24
60-69 38 40
$70 38 30
Previous cardiovascular procedure
LEB, CEA, AAA 15 18 .085
CABG/PCI 24 23 .674
Comorbidity
Diabetes 26 25 .692
Hypertension 83 80 .026
Dialysis dependent 1.4 0.6 .038
COPD 38 42 .021
Living at home
preadmission
99 99 .122
Procedure type .003
AAA repair
Open 50 50
Endovascular 49 51
LEB 46 54
CEA 43 57
CAS 27 73
Perioperative
Urgent or emergent
procedure
13 12 .319
Length of stay >2 days 45 38 <.001
Intensive care unit stay 45 45 .96
Discharge destinationa <.001
Home 89 94
Rehabilitation unit 7 4
Nursing home 3 2
AAA, Abdominal aortic aneurysm; CABG, coronary artery bypass grafting;
CAS, carotid artery stenting; CEA, carotid endarterectomy; COPD, chronic
obstructive pulmonary disease; LEB, lower-extremity bypass; PCI, percu-
taneous coronary intervention.
aColumn percent. Values have been rounded and may not sum to 100%.
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cessation by the time of follow-up. The patients who quit
smoking are compared in Table II with those who continued
smoking. Smoking cessation was associated with multiple
patient-related and procedure-related factors. In particular,
there was signiﬁcant variability in smoking cessation rates
depending on patient age, comorbidity (hypertension, dia-
betes, COPD), and procedure. The procedure-speciﬁc
variability in cessation rate is shown in Fig 1. Smoking
cessation was also associated with LOS >2 days and
discharge to a rehabilitation center or nursing home.
Multivariate analysis of patient characteristics demon-
strated that patients were more likely to quit smoking if
they had hypertension, dialysis-dependent renal failure, orwere aged >70 years. In contrast, patients who had
COPD were less likely to quit smoking (Table III). Consis-
tent with smoking cessation rates by procedure type,
patients undergoing oAAA repair had a signiﬁcantly higher
likelihood of smoking cessation at 1 year, and patients
undergoing EVAR or LEB had a strong trend toward
increased smoking cessation. In contrast, patients under-
going CAS were less likely to quit smoking after their
procedure. The area under the receiver operating charac-
teristic curve for this logistic model was 0.58, demon-
strating that smoking cessation can only partially be
explained by patient characteristics or procedure type.
Variation in cessation rates by treatment center. We
considered the contribution of the treatment center to
better understand the signiﬁcance of processes of care in
smoking cessation. The c-pie analysis of a multivariable
Table III. Multivariate analysis of patient factors and
procedure type associated with smoking cessationa
Variable OR (95% CI) P
Age, years
<50 Reference
50-59 1.20 (0.82-1.75) .356
60-69 1.42 (0.98-2.05) .065
$70 1.90 (1.30-2.76) <.001
Comorbidity
Dialysis 2.38 (1.04-5.43) .040
Hypertension 1.23 (1.00-1.51) .051
COPD 0.76 (0.65-0.90) .001
Procedure type
Carotid endarterectomy Reference
AAA repair
Open 1.30 (1.03-1.63) .027
Endovascular 1.23 (0.94-1.62) .136
Lower-extremity bypass 1.19 (0.98-1.44) .086
Carotid artery stenting 0.50 (0.27-0.92) .025
AAA, Abdominal aortic aneurysm; CI, conﬁdence interval; COPD, chronic
obstructive pulmonary disease; OR, odds ratio.
aArea under the curve ¼ 0.58.
Fig 2. The relative contribution of factors included in the multi-
variable model to explain the variation in rates of smoking cessation.
The treatment center explains nearly 75% of the variation within the
model, whereas patient factors and procedure type explain the
remaining portion of the variation in the model. COPD, Chronic
obstructive pulmonary disease; HTN, hypertension.
Fig 1. Rates of smoking cessation shown by procedure type (P ¼
.003). CAS, Carotid artery stenting; CEA, carotid endarterectomy;
EVAR, endovascular aneurysm repair; LEB, lower extremity
bypass; oAAA, open abdominal aortic aneurysm.
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the signiﬁcant variables within the model, 75% of the vari-
ation in cessation rates could be attributed to the treatment
center and only 25% to patient factors (Fig 2).
Observed smoking cessation rates varied signiﬁcantly
between centers, from 28% to 62%, whereas the expected
rates of smoking cessation based on patient characteristics
and procedure type showed little variation among centers
(43% to 47%). Supporting this comparison with analysis
of means, which provides an expected range around the
mean, demonstrated cessation rates that were signiﬁ-
cantly below expected for two centers (centers 1 and 2)
and were above expected for three centers (centers 7, 9,
and 10; Fig 3).Our provider survey further explored surgeon-speciﬁc
variation in cessation rates. In the survey, 82% of surgeons
estimated that more than half of their patients were current
smokers, in contrast with a 33% smoking prevalence in the
study cohort. When asked about postoperative smoking
cessation, half of respondents estimated a cessation rage
of <25% compared with the actual cessation rate of 45%.
All respondents reported that they discussed smoking
cessation with their patients during one or more clinical
encounters in the perioperative period.
There was broad variation in cessation interventions
the surgeons offered to patients: 15% offered referral to
a smoking cessation specialist, 33% offered pharmaco-
therapy, 30% offered a combination of referral and pharma-
cotherapy, and 22% left all smoking cessation treatment to
the primary care provider. A univariate comparison using
these survey responses demonstrated signiﬁcantly higher
cessation rates for patients offered pharmacotherapy or
referral to a specialist than for patients sent back to their
primary care provider for smoking cessation treatment
(48% vs 33%; P < .004).
DISCUSSION
Cigarette and tobacco smoking is a complex public
health problem with signiﬁcant implications for the
secondary prevention of cardiovascular disease. Although
the population prevalence of smoking has decreased in
the last 45 years, the cessation rate (deﬁned as 6-months
abstinence from tobacco) was estimated to be only w6%
Fig 3. Treatment center level comparisons are shown using observed/expected and analysis of means. The treatment
center number is arbitrarily assigned in this graph. P < .05 for values outside of upper and lower limits. VSGNE,
Vascular Study Group of New England.
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tion rate of 45% within 1 year of patients undergoing
vascular surgery, markedly exceeding the estimated cessa-
tion rate for the population. Importantly, this cessation
rate occurs in the context of a 33% smoking prevalence
among patients in our cohort, which exceeds the estimated
population prevalence of 19%. Although this is the ﬁrst
such report in vascular surgery patients, the 1-year cessa-
tion rate is consistent with rates observed in studies of other
surgery patients. Two observational studies of cardiac
surgery patients demonstrated smoking cessation rates of
50% and 55% at 1 year.20,21 In a randomized trial, smoking
cessation before general or orthopedic procedures resulted
in a 40% smoking cessation rate.22
Our analysis has delineated multiple factors associated
with perioperative smoking cessation. Of these, the two
most important are (1) that more invasive procedures
tend to have higher cessation rates and (2) that for multiple
reasons, there is a signiﬁcant variation in cessation rates
between treatment centers. The effect of procedure inva-
siveness is seen in raw cessation rates by procedure as
well as in multivariate analysis, where more invasive proce-
dures—oAAA in particular—have higher odds ratios for
smoking cessation. Not surprisingly, the strong covariates
of procedure invasiveness, LOS, and discharge destination
were also signiﬁcant on univariate analysis.
This relationship between procedure invasiveness and
smoking cessation was also demonstrated in study of
patients treated for coronary artery disease, where a higher
rate of smoking cessation was shown after CABG (55%)
than after a percutaneous coronary intervention (25%)
and angiography alone (14%) at 1 year.20 Another study
found that patients undergoing major surgery had a higher
likelihood of smoking cessation than those undergoing an
outpatient procedure (odds ratio, 2.02 vs 1.28).23 Indeed,
a number of studies have shown a higher rate of smokingcessation with counseling around the time of a hospital
admission or surgical intervention, highlighting what has
been described as a “teachable moment.”23,24
The broad variation in cessation rates across treatment
centers is the second key point of our analysis. The low
area under the curve in our multivariable analysis of patient
factors and procedure type clearly indicates that diverse
factors are associated with smoking cessation that are not
explained by our model. Indeed, subsequent analysis
demonstrated that 75% of the variation in cessation rate
could be attributed to the treatment center, far more signif-
icant than patient factors or procedure type. This is further
demonstrated in looking at treatment centers individually
and noting cessation rates in two centers that were lower
than predicted, which strongly contrasts with the high cessa-
tion rates in other centers. Although direct comparison of
this ﬁnding to physician practices is not possible, the
provider survey does offer some additional insight into these
observations. In particular, it appears that that surgeons
offering more aggressive smoking cessation interventions,
such as referral to a specialist or offering pharmacotherapy
or both, are more likely to have patients that quit smoking.
Unfortunately, the survey also suggests that many
surgeons think the problem is more daunting than it is in
the way that respondents overestimated the smoking preva-
lence in the population. Further, underestimating the rate of
perioperative smoking cessation suggests that many
surgeonsmisjudge the effect they canhave on smoking cessa-
tion for their patients.
Although there are no studies from prospectively
collected data regarding smoking cessation in the vascular
surgical population, a study of medical patients with PAD
found treatment with intensive counseling and medication
resulted in a cessation rate of 21.3% at 6 months compared
with a cessation rate of 6.8% in a minimal intervention
group.25 A study in medical patients demonstrated a higher
JOURNAL OF VASCULAR SURGERY
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tion counseling after a major medical illness.26
The regional variation in cessation rates and the impor-
tance of the physician and treatment center in smoking cessa-
tion are particularly important when considered in the
context of the additional signiﬁcant elements in our multi-
variable model. In particular, patients aged >70 years and
patients with additional comorbidities of hypertension and
dialysis-dependence were more likely to quit smoking. The
one contrast to this assessment is that having COPD appears
to decrease the odds of smoking cessation. Although this
particular ﬁnding is not well delineated by the available
data, it may reﬂect a patient cohort refractory to cessation
interventions; that is, patients with a diagnosis of COPD
who were able to quit smoking would already have done so
upon diagnosis of their pulmonary disease. However, in
total, our analysis suggests that in younger patients with
fewer comorbidities—the patients who have the greatest
potential to beneﬁt from smoking cessation—are the
patients least likely to quit. This represents a high-impact
opportunity for targeted secondary prevention.
This study has several important limitations, the most
important of which is that smoking cessation in this data
set is self-reported by the patient and no conﬁrmatory
biochemical testing was performed. This method of data
collection can lead to patient under-reporting of current
smoking. However, there are four particular factors that
support the validity of this methodology in this study:
First, a high sensitivity of patient-reported smoking
status was demonstrated by a meta-analysis of studies
examining smoking status and by a large population-
based study of smoking.27,28
Second, because the data are collected as part of
a clinical encounter, they are likely less susceptible to the
potential dishonesty that is noted to be more likely in
survey-based studies.27
Third, collection of data from a clinical encounter also
provides additional clinical relevance to the clinical practice
of vascular surgery, particularly when considering that
a performance measure similar to the one being imple-
mented by The Joint Commission would be based on
patient-reported data.16
Fourth, the perceived gold standard of biochemical
testing has been questioned in the literature because there
is a signiﬁcant portion of false-negative reports, likely due
to the insensitivity of the most widely available assay
methods.28 Importantly, even if smoking status were
underestimated in this cohort, there are no data to suggest
a systematic bias that would invalidate the relative changes
and effects of different operations and centers.
The second study limitation is the lack of follow-up
data regarding smoking status in 27% of the patients. The
likelihood of this introducing a bias within the entire
cohort is limited by the lack of disparity in the patient level
data between those who did and did not have follow-up.
However, there is potential for introduction of bias at the
center level, and we did note a degree of inverse correlation
between centers that had higher follow-up among currentsmokers and lower cessation rates (r ¼ 0.57; P ¼ .087).
This limitation has three potential components: (1)
decreased reporting of continued smoking by patients at
follow-up, (2) decreased follow-up by patients who
continue smoking, or (3) decreased reporting by physicians
and centers for patients who continue smoking. Each
component is relevant for future quality improvement
within our regional study group. However, the signiﬁcant
inﬂuence of center in our analysis of smoking cessation
and the broad variation in cessation rates by center are
very unlikely to be abrogated by more uniform follow-up
in our cohort.
The ﬁnal study limitation is the lack of external valida-
tion of our provider survey before administration. The
survey had excellent response rates, but the lack of valida-
tion limited our ability to standardize the responses using
the full multivariable model. However, none of these limi-
tations diminish the key ﬁndings from this data.
CONCLUSIONS
Our study shows that the magnitude of vascular
surgical reconstruction is directly related to the chance
that the patient will stop smoking. Of greater signiﬁcance,
however, is the broad variation in smoking cessation rates
between centers participating in the VSGNE. This analysis
suggests that center-speciﬁc strategies are important deter-
minants of success or failure in getting patients to quit
smoking. The need for greater attention to smoking and,
by extension, smoking cessation at the center level is
further highlighted by the variable follow-up observed
among smokers at each center. Using the framework built
by our regional quality collaborative, our future work will
identify how those centers and surgeons with both high
follow-up rates and high smoking cessation rates accom-
plish this task. This will facilitate expansion of these tech-
niques to all centers in our region.
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should take less than 5 minutes to complete. Please answer as completely as possible, but do not spend time looking-
up answers or seeking additional information. It is as much a survey of perceptions as a survey of resources. You 
will not be identified. 
By your estimate, what percentage of your patients who require surgery for arterial disease smoke at the time of 
your preoperative assessment? 
0-24% 
25-49% 
50-74% 
75-100% 
What percentage of these patients do you think quit smoking during the first year after surgery? 
0-24% 
25-49% 
50-74% 
75-100% 
Do you address smoking cessation with your patients in the following situations? (check all that apply) 
Every clinical encounter 
Initial consultation 
During inpatient stay
During post-operative visit 
Other (specify)______________________________ 
I don’t routinely address smoking cessation 
How much time to you personally spend in a typical session addressing smoking cessation? 
< 3 minutes 
3-10 minutes 
> 10 minutes  
What do you personally offer your patient’s that smoke (check all that apply)? 
Varenicline (Chantix) 
Buproprion (Zyban) 
Nicotine replacement (patch, gum, other) 
Referral to a smoking cessation specialist, service or support group 
Referral back to primary care provider for smoking cessation 
Other (specify) __________________ 
What interventions/services are available at your hospital/clinic? 
Smoking cessation consult service 
Support group(s) 
Other (specify) ________________ 
Don’t know 
How often do you use the CPT codes 99406 or 99407 – smoking cessation counseling -  in your office billing? 
Never 
Occasionally 
Often 
What is your smoking status? 
Current smoker (within past year) 
Past smoker  
Never smoker 
Supplementary Fig. Smoking cessation survey. CPT, Current Procedural Terminology (American Medical Associa-
tion, Chicago, Ill); VSGNE, Vascular Study Group of New England.
